PATENT CLAIM ANALYSIS

Application Number: 16144549
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["424", "133100"]

Abstract:
Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.

Claim (Index 25):
The method of  claim 17 , wherein the outcome that is improved is an improved objective response rate (ORR), an improved progression-free survival (PFS), or an improved overall survival.

Metadata:
- Claim Count in Document: 25.0
- Percentile: 97.0
- Lexical Diversity: 1.25
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14852664', '13860422', '15613192', '14284706', '14506565']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7801617445079974
- 35 USC 102 Novelty (BERT): 0.5317550299220093
- Combined Prediction Score: 0.7553210730493987
- Mean Citation Score: 336.85155999999995
- Max Citation Score: 356.52682000000016
- Similarity Product: 219.5671807872713

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test